KR20240004433A - Ert2 돌연변이체 및 이의 용도 - Google Patents

Ert2 돌연변이체 및 이의 용도 Download PDF

Info

Publication number
KR20240004433A
KR20240004433A KR1020237037724A KR20237037724A KR20240004433A KR 20240004433 A KR20240004433 A KR 20240004433A KR 1020237037724 A KR1020237037724 A KR 1020237037724A KR 20237037724 A KR20237037724 A KR 20237037724A KR 20240004433 A KR20240004433 A KR 20240004433A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid substitution
optionally
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237037724A
Other languages
English (en)
Korean (ko)
Inventor
미셸 엘리자베스 헝
레베카 테일러 콧먼
러셀 모리슨 골들리
개리 이
티모시 관-타 루
스리니바사라가반 칸난
찬드라 셰커 베르마
Original Assignee
센티 바이오사이언시스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센티 바이오사이언시스, 인코포레이티드 filed Critical 센티 바이오사이언시스, 인코포레이티드
Publication of KR20240004433A publication Critical patent/KR20240004433A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020237037724A 2021-04-06 2022-04-06 Ert2 돌연변이체 및 이의 용도 Pending KR20240004433A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171227P 2021-04-06 2021-04-06
US63/171,227 2021-04-06
PCT/US2022/023673 WO2022216823A1 (en) 2021-04-06 2022-04-06 Ert2 mutants and uses thereof

Publications (1)

Publication Number Publication Date
KR20240004433A true KR20240004433A (ko) 2024-01-11

Family

ID=83546546

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037724A Pending KR20240004433A (ko) 2021-04-06 2022-04-06 Ert2 돌연변이체 및 이의 용도

Country Status (9)

Country Link
US (1) US20240150433A1 (cg-RX-API-DMAC7.html)
EP (1) EP4320228A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513231A (cg-RX-API-DMAC7.html)
KR (1) KR20240004433A (cg-RX-API-DMAC7.html)
CN (1) CN117321192A (cg-RX-API-DMAC7.html)
AU (1) AU2022255180A1 (cg-RX-API-DMAC7.html)
CA (1) CA3213591A1 (cg-RX-API-DMAC7.html)
IL (1) IL307269A (cg-RX-API-DMAC7.html)
WO (1) WO2022216823A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024163908A2 (en) * 2023-02-02 2024-08-08 Senti Biosciences, Inc. Improved ert2 mutants, inducible cell death systems, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002097050A2 (en) * 2001-05-31 2002-12-05 Novartis Ag Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
CA2485939C (en) * 2002-05-29 2013-10-29 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US20070087346A1 (en) * 2003-10-24 2007-04-19 Gennaro Ciliberto Orthogonal gene switches
WO2014172470A2 (en) * 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
EP3585394A4 (en) * 2017-02-23 2021-06-30 Olema Pharmaceuticals, Inc. COMPOSITIONS AND PROCEDURES FOR REGULATING IMMUNE SYSTEM ACTIVITY
KR102109820B1 (ko) * 2018-04-16 2020-05-12 한양대학교 산학협력단 비스페놀 a와의 결합력이 향상된 돌연변이 에스트로겐 수용체 단백질 및 이를 이용한 박테리아 균주

Also Published As

Publication number Publication date
CN117321192A (zh) 2023-12-29
IL307269A (en) 2023-11-01
CA3213591A1 (en) 2022-10-13
EP4320228A4 (en) 2025-07-02
AU2022255180A1 (en) 2023-11-16
JP2024513231A (ja) 2024-03-22
EP4320228A1 (en) 2024-02-14
WO2022216823A1 (en) 2022-10-13
US20240150433A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
US12599678B2 (en) Methods and compositions for genomic integration
AU2019204429B2 (en) Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
KR102451510B1 (ko) Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
KR20200032174A (ko) 강화된 키메라 항원 수용체 및 이의 용도
CN112262214A (zh) 病毒载体及包装细胞系
KR102628872B1 (ko) 세포의 증식을 제어하기 위해 세포 분열 좌위를 사용하기 위한 도구 및 방법
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
KR20240001708A (ko) 유전적 장애의 치료를 위해 생체내 뉴클레아제-매개의 유전자 표적화를 위한 조성물 및 방법
CN113817775B (zh) 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用
KR20240037192A (ko) 게놈 통합을 위한 방법 및 조성물
WO2024163805A1 (en) Methods and compositions for genomic integration
CN117693592A (zh) 用于治疗遗传性疾患的体内核酸酶介导的基因靶向的组合物和方法
CN113667017A (zh) 一种可提高CRISPR/Cas9系统同源重组效率的方法和应用
JP2024513231A (ja) Ert2変異体及びその使用方法
HK40082332B (en) Tools and methods for using cell division loci to control proliferation of cells
HK40082332A (zh) 使用细胞分裂基因座控制细胞增殖的工具和方法
HK40109263A (en) Compositions and methods for in vivo nuclease-mediated gene targeting for the treatment of genetic disorders
HK40091239A (en) Compositions and methods for targeting hpv-infected cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231101

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250327

Comment text: Request for Examination of Application